Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional

Study to Assess the Effects of Oral NMRA-335140 in Participants With Major Depressive Disorder

ClinicalTrials.gov ID: NCT06058039

Public ClinicalTrials.gov record NCT06058039. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 3:11 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effects of Oral NMRA-335140 Versus Placebo in Participants With Major Depressive Disorder

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This randomized, double-blind, placebo-controlled, multicenter study will evaluate the effects of NMRA-335140 (formerly BTRX-335140) on symptoms of depression in participants with Major Depressive Disorder (MDD). The study design consists of a Screening Period (up to 35 days), and a 6-week Treatment Period (during which participants will receive either NMRA-335140 or placebo). At the completion of the 6-week Treatment Period, participants who complete the study, provide informed consent, and meet the eligibility criteria may enter an open-label extension study (NMRA-335140-501).

Study identification

NCT ID
NCT06058039
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Neumora Therapeutics, Inc.
Industry
Enrollment
422 participants

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years to 65 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Dec 21, 2023 (Actual)
Primary completion
May 4, 2026 (Actual)
Completion
Jun 11, 2026 (Actual)
Last update posted
Jul 6, 2026

2023 – 2026

United States locations

U.S. sites
34
U.S. states
11
U.S. cities
30
Facility City State ZIP Site status
Neumora Investigator Site Cerritos California 90703 —
Neumora Investigator Site Irvine California 92614 —
Neumora Investigator Site Long Beach California 90807 —
Neumora Investigator Site San Diego California 92103 —
Neumora Investigator Site San Francisco California 94107 —
Neumora Investigator Site New Haven Connecticut 06520 —
Neumora Investigator Site Brandon Florida 33511 —
Neumora Investigator Site Hialeah Florida 33012 —
Neumora Investigator Site Hialeah Florida 33016 —
Neumora Investigator Site Jacksonville Florida 32256 —
Neumora Investigator Site Miami Florida 33143 —
Neumora Investigator Site Miami Florida 33165 —
Neumora Investigator site Miami Florida 33174 —
Neumora Investigator Site Miami Beach Florida 33140 —
Neumora Investigator site Miami Springs Florida 33166 —
Neumora Investigator Site Palm Bay Florida 32905 —
Neumora Investigator Site Pembroke Pines Florida 33024 —
Neumora Investigator Site Pompano Beach Florida 33060 —
Neumora Investigator Site Saint Augustine Florida 32086 —
Neumora Investigator Site Atlanta Georgia 30328 —
Neumora Investigator Site Decatur Georgia 30030 —
Neumora Investigator Site Savannah Georgia 31405 —
Neumora Investigator Site Springfield Massachusetts 01103 —
Neumora Investigator Site St Louis Missouri 63141 —
Neumora Investigator Site Omaha Nebraska 68112 —
Neumora Investigator Site Berlin New Jersey 08009 —
Neumora Investigator Site New York New York 10029 —
Neumora Investigator Site New York New York 10036 —
Neumora Investigator Site Staten Island New York 10310 —
Neumora Investigator Site Charlotte North Carolina 28211 —
Neumora Investigator Site Austin Texas 78759 —
Neumora Investigator Site DeSoto Texas 75115 —
Neumora Investigator Site Fort Worth Texas 76104 —
Neumora Investigator Site Plano Texas 75093 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 37 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT06058039, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jul 6, 2026 · Synced Oct 28, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT06058039 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →